Commit Biologics is a biotech spin-out from Aarhus University in Denmark – an academic institution with a global reputation in complement system biology from more than three decades of complement research. Our Bispecific Complement Engaging technology (BiCE™) is designed to potently activate the complement system to induce highly-selective killing of tumor cells or cells implicated in autoimmune disease. BiCE™ uses single domain antibodies that bind to the complement protein C1q, consequently directing the complement system in a highly targeted way against cells of interest. With a novel mechanism of action, the technology has the potential to redefine the treatment of cancer and autoimmune disease.
